ArticleEmergency medicine Australasia : EMA2026
Analytically Confirmed Opioid Detections From the Emerging Drugs Network of Australia.
Article in Emergency medicine Australasia : EMA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Negative Suicide-Intent Entry Is Not a Stable Endpoint in Opioid Toxicovigilance.Emergency medicine Australasia : EMA · 2026Article
- Analytically Confirmed Opioid Detections From the Emerging Drugs Network of Australia.Emergency medicine Australasia : EMA · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveWe describe analytically confirmed opioid-related presentations to emergency departments (EDs) in Australia.
methodsPresentations with analytically confirmed opioid exposure, between January 2021 and December 2024, were identified from the Emerging Drugs Network of Australia (EDNA) Clinical Registry. Demographic data, clinical features, outcomes, naloxone dosing, and analytical toxicology results were extracted.
resultsOpioids were detected in 793 ED presentations. The majority were male (568, 71.6%) with a median age of 40 years (Q1-Q3: 30-48 years). Patients were unwell (Australasian Triage Score 1 or 2 = 700, 88.3%). Suicidal intent was noted in 55 (6.9%) presentations. Mono-opioid detections occurred in 550 (69.4%) presentations, most frequently heroin exposures (162, 29.5%). Novel opioids including nitazenes and U-Class synthetic opioids were uncommon (21, 2.6%). Illicit co-detections were common (547, 69.0%) especially with methylamphetamine (512, 64.6%), gamma-hydroxybutyrate (108, 13.6%), and diazepam (341, 43%). Naloxone was used in 498 (62.8%) presentations: median dose 400 μg (IQR: 200-600 μg). There was no difference in median naloxone dose for heroin (median 320 μg) and novel opioids (median 500 μg, p = 0.25). Intubation was more likely to occur in patients with novel opioids compared to heroin (8/21, 26/162, p = 0.020).
conclusionsHeroin was the most common analytically confirmed illicit opioid detected among opioid-related ED presentations. Novel opioids were uncommon with no difference in median naloxone dose used. There were higher intubation rates for novel opioids. Polydrug exposure is common, complicating the clinical picture. Increased awareness of the national Take Home Naloxone program, particularly by emergency physicians, is a key element of harm reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.